Adjuvant chemotherapy for resectable gastric cancer: A preliminary report

Fong‐Fu ‐F Chou*, Shyr‐Ming ‐M Sheen‐Chen, Po‐Pen ‐P Liu, Feng‐Chi ‐C Chen

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

26 Scopus citations


In this prospectively random study, the effect of oral Ftorafur as an adjuvant chemotherapy was compared with that of oral placebo in patients with Stage II and Stage III gastric cancer. Patients had undergone a subtotal gastrectomy with a resection margin that should have been free of tumors. Ftorafur (10 mg/kg) was given daily to 59 Group A patients. Multiple vitamins were given twice a week to 56 Group B patients. We found that there was no statistical significance in Stage II patients with regard to survival. In Stage III patients, those treated with oral Ftorafur had better ‐3‐year and 5‐year survival rates than those receiving oral placebo. This preliminary report on this ongoing study seems to indicate that long‐term postoperative Ftorafur treatment may be beneficial to Stage III gastric cancer patients. © 1994 Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)239-242
Number of pages4
JournalJournal of Surgical Oncology
Issue number4
StatePublished - 12 1994
Externally publishedYes


  • Ftorafur
  • adjuvant chemotherapy
  • oral placebo
  • subtotal gastrectomy


Dive into the research topics of 'Adjuvant chemotherapy for resectable gastric cancer: A preliminary report'. Together they form a unique fingerprint.

Cite this